Bioaltus Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.10 Cr
as on 16-11-2024
- Paid Up Capital ₹ 1.12 Cr
as on 16-11-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 16.50 Cr
as on 16-11-2024
- Revenue 142.00%
(FY 2023)
- Profit 112.63%
(FY 2023)
- Ebitda 111.59%
(FY 2023)
- Net Worth 7.41%
(FY 2023)
- Total Assets 34.72%
(FY 2023)
About Bioaltus Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.10 Cr and a paid-up capital of Rs 1.12 Cr.
The company currently has active open charges totaling ₹16.50 Cr.
Sanket Patil and Siya Patil serve as directors at the Company.
- CIN/LLPIN
U74900MH2015PTC264964
- Company No.
264964
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 May 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Bioaltus Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanket Patil  | Managing Director | 28-May-2015 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Siya Patil | Additional Director | 07-Mar-2023 | Current |
Financial Performance of Bioaltus Laboratories.
Bioaltus Laboratories Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 142% increase. The company also saw a substantial improvement in profitability, with a 112.63% increase in profit. The company's net worth moved up by a moderate rise of 7.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bioaltus Laboratories?
In 2023, Bioaltus Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Aikvira Pharmaceuticals Private LimitedActive 1 year 7 monthsSanket Patil and Siya Patil are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 07 May 2024 | ₹16.50 Cr | Open |
How Many Employees Work at Bioaltus Laboratories?
Unlock and access historical data on people associated with Bioaltus Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bioaltus Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bioaltus Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
